A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activityof LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with MetastaticSolid Tumors

Contact:

NCT Number:

Protocol:

AAAT5289

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I/II

This is the first research study of LYT-200 in people and the main purpose of this study is to test the safety and tolerability of LYT-200. LYT-200 is intended to inhibit (hinder) galectin 9. Galectin 9 is a protein which suppresses immune function and disables the immune system’s attack on cancer through multiple ways. In this study we shall also examine how the drug is changed by and removed from the body and will look for signs that the drug may be truly effective against cancer.

Are you Eligible? (Inclusion Criteria)

  • Have you been diagnosed with unresectable metastatic cancer?
  • Have you received 1 prior line of systemic therapy for your cancer?
  • Are you aged 18 or older?

Specialty Area(s)

Colon and Rectal Cancer, Liver Cancer, Lung cancer, Pancreatic Cancer, Immunotherapy

Principal Investigator

Profile Headshot
  • Director of Medical Oncology and Translational Research for The Pancreas Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032